Finance entity
Every one of those 1 sits in a single category, earnings. Of the tracked stories, 1 of 1 also mention Profound Medical, the most common co-covered peer. The 5 average consequence score is below the beat benchmark of 6.3 in the same window.
Last mentioned: Mar 6, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, earnings. Of the tracked stories, 1 of 1 also mention Profound Medical, the most common co-covered peer. The 5 average consequence score is below the beat benchmark of 6.3 in the same window. Source depth averages 2 original sources per story, versus 2.4 across the same-window beat baseline. Kura Oncology appears in 1 tracked Finance story from March 6, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 95 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Kura Oncology. Shared-story counts are live from our verified record — not editorial picks.
PROF Break-even
Target window for Profound Medical to reach cash-flow neutrality.
Kura NDA Submission
Anticipated filing for ziftomenib with the FDA.
Q4 Earnings Release
Both companies report pivotal year-end results.
CPT Code Activation
Category 1 CPT codes for TULSA-PRO go live in the U.S.
Kura Oncology and Profound Medical reported Q4 2025 results, highlighting a pivotal shift toward commercial execution. Kura is nearing an NDA submission for its lead leukemia candidate, while Profound saw record revenue growth following the first full year of Category 1 CPT code implementation.
Kura Oncology is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
